Tagged with GE

LatAm Diego Ocampo, Vice President of Technology at Neolpharma and President of the Mexican Foundation for Health Innovation (INCIDE), represents a new generation of pharmaceutical leadership combining global perspective with regional expertise. Having pursued graduate studies in medicinal chemistry at Tokyo University following his undergraduate work at UNAM, Ocampo has spent…

LatAm From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already considered global standards. According to the Waiting to Access Innovative Therapies (W.A.I.T.) Indicator from FIFARMA, an association representing research-based pharma…

UAE Adeeb Al Attar leads Genpharm at a point where rare and advanced therapies in the Middle East face a more exacting test. Scale and ambition are no longer enough. What matters now is execution, credibility, and the ability to move innovation through complex healthcare systems without losing focus. In this…

USA Alberto Santagostino, CEO of AGC Biologics, discusses how the company is positioning itself in an increasingly regionalized CDMO market, the strategic value of its global manufacturing footprint, and the role of technical expertise and long-term partnerships in supporting advanced biologics and cell and gene therapy programs. Santagostino goes on to…

France Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new expectations of industry-public collaboration. In this interview, Marina Vasiliou reflects on how these forces are reshaping the affiliate’s mission, the…

Tags: USA Manisha Balwani is Chief of the Division of Medical Genetics and Genomics at Icahn School of Medicine at Mount Sinai, where she leads programs spanning genetic screening, diagnosis, clinical trials, and treatment across the lifespan. In this interview, she discusses how Mount Sinai supports rare disease patients from early identification…

USA Charlene Son Rigby, CEO of Global Genes, shares her insights on the rapidly evolving rare disease landscape. She highlights exciting developments such as patient-driven research and development and the future potential of platform technologies and individualized medicines. Drawing from her personal experience, Charlene also emphasizes the critical importance of ongoing…

LatAm Latin America faces one of the most complex healthcare landscapes in the world, where fast-growing demand collides with deep structural inequities and limited resources. In this interview, Fabrizio Signorin, President Latin America at Siemens Healthineers, shares how the organisation is working with governments and providers to reimagine care delivery, expand…

France Dominique Pezziardi oversees International Commercial Operations for Stallergenes Greer, a global biotechnology company specialising in allergy therapeutics. With more than 1,200 employees globally – over 600 based in France – the company maintains a unique positioning as a Swiss-headquartered organisation with deep French industrial roots. Under Pezziardi’s 13-year tenure across…

Hong Kong Professor Samuel Au, Founder and CEO of Cornerstone Robotics, recounts his journey from business to academic research to building one of Asia’s most promising surgical robotics ventures. He explains how the Sentire® Surgical System is redefining precision, access, and training in operating rooms worldwide, combining Hong Kong’s innovation ecosystem with…

Argentina Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical market and the high-cost speciality products segment, a feat that requires markedly different capabilities. Leveraging full vertical integration and a…

Brazil Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology transfer agreements is bolstering local manufacturing capabilities and helping these companies scale the value chain. Multinationals – with the right…